Hiscox, Stephen - Cardiff University - School of Pharmacy and Pharmaceutical Sciences

个人简介

I joined the Metastasis Research Group within the University of Wales College of Medicine as a member of research staff in 1993. I received the American Association for Cancer Research Young Investigators Award in 1998 and, in 1999, attained my PhD and received a University of Wales College of Medicine Senior Research Fellowship in recognition of my contribution to research within the college. After spending a further 3 years within this group, I joined the Tenovus Centre for Cancer Research in 2001. In 2007, I was awarded an RCUK Academic Fellowship to enable me to pursue my research and teaching interests in the field of cancer invasion and metastasis within the School of Pharmacy and Pharmaceutical Sciences, Cardiff University. Promotion to Senior Lecturer in the School followed in 2012.

研究领域

Having previously trained in the field of cancer metastasis, my research interests are concerned with studying how tumour cells develop a metastatic phenotype, how drug resistance contributes to this process and exploring the role of the tumour microenvironment as a modulator of such behaviour. The goal of these studies is to reveal clinical markers of drug response/relapse and clinical targets through which tumour spread can be repressed. Breast cancer and acquired drug resistance Tumour invasion and metastasis Influence of the tumour microenvironment in tumour progression and spread

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Wymant, J.et al. 2016. The Role of BCA2 in the endocytic trafficking of EGFR and significance as a prognostic biomarker in cancer. Journal of Cancer 7(15), pp. 2388-2407. (10.7150/jca.15055) pdf Bellerby, R.et al. 2016. Overexpression of specific CD44 isoforms is associated with aggressive cell features in acquired endocrine resistance. Frontiers in Oncology 6, article number: 145. (10.3389/fonc.2016.00145) pdf Gangadhara, S.et al. 2016. 3D culture of Her2+ breast cancer cells promotes AKT to MAPK switching and a loss of therapeutic response. BMC Cancer 16(1), article number: 345. (10.1186/s12885-016-2377-z) pdf Elseginy, S.et al. 2015. Computer-aided identification of novel anticancer compounds with a possible dual HER1/HER2 inhibition mechanism. Biorganic and Medicinal Chemistry Letters 25(4), pp. 758-762. (10.1016/j.bmcl.2014.12.095) pdf Wiggins, H.et al. 2015. Disulfiram-induced cytotoxicity and endo-lysosomal sequestration of zinc in breast cancer cells. Biochemical Pharmacology 93(3), pp. 332-342. (10.1016/j.bcp.2014.12.014) pdf Lazaro, G.et al. 2013. Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response. Endocrine Related Cancer 20(5), pp. 691-704. (10.1530/ERC-13-0019) Hogstrand, C.et al. 2013. A mechanism for epithelial–mesenchymal transition and anoikis resistance in breast cancer triggered by zinc channel ZIP6 and STAT3 (signal transducer and activator of transcription 3). Biochemical Journal 455(2), pp. 229-237. (10.1042/BJ20130483) pdf Eccles, S.et al. 2013. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research 15(5), pp. R92. (10.1186/bcr3493) pdf Gangadhara, S.et al. 2012. Pro-metastatic tumor-stroma interactions in breast cancer. Future Oncology 8(11), pp. 1427-1442. (10.2217/fon.12.134.) Hiscox, S.et al. 2012. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. BMC Cancer 12, article number: 458. (10.1186/1471-2407-12-458) pdf Taylor, K.et al. 2012. Protein kinase CK2 triggers cytosolic zinc signaling pathways by phosphorylation of zinc channel ZIP7. Science Signaling 5(210), article number: ra11. (10.1126/scisignal.2002585) pdf